Clinical Trials Directory

Trials / Completed

CompletedNCT00482352

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Classification Of Acute Lymphoblastic Leukemia

Status
Completed
Phase
Study type
Observational
Enrollment
11,196 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
1 Year – 30 Years
Healthy volunteers
Not accepted

Summary

This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.

Detailed description

OBJECTIVES: I. Provide a classification guide that will organize the clinical and laboratory data necessary for assigning each patient with newly diagnosed acute lymphoblastic leukemia (ALL) to a specific treatment clinical trial. II. Provide an administrative base to capture classification data for correlative studies accompanying current Children's Oncology Group (COG) ALL treatment clinical trials. III. Provide a central reference guide for all required and research only ALL studies that will be conducted at local and reference laboratories. IV. Provide a mechanism for optional banking of leukemia and germline specimens for current and future research. OUTLINE: Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia). After completion of induction therapy, patients are followed once or twice annually.

Conditions

Interventions

TypeNameDescription
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2003-12-01
Primary completion
2012-04-01
Completion
2023-06-30
First posted
2007-06-05
Last updated
2023-08-03

Locations

200 sites across 6 countries: United States, Australia, Canada, New Zealand, Puerto Rico, Switzerland

Source: ClinicalTrials.gov record NCT00482352. Inclusion in this directory is not an endorsement.